Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Home CompaniesShield Therapeutics plc

Shield Therapeutics plc

Healthcare Drug Manufacturers - Specialty & Generic
PortfolioPortfolio WatchlistWatchlist
Company price
5.33 GBX -0.17 ( 3.09%)
Last update at 2026-10-27T16:01:00Z
VOLUME
545025
Market Cap
95.05M

Momentum Score

…

Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
5.30
Low
5.60
High
52 Week Price Range
2.10
Low
12.50
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
5.50
Dividend Yield
-
Revenue TTM
41.49M
Revenue Per Share
0.04
Gross Profit TTM
20.06M
Debt / Equity
-20.02
ROE
-396.36%
Net Debt
15.45M
ROCE
-89.14%
Diluted EPS TTM
-0.01

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -20.78M -32.38M -40.08M -19.57M -1.89M
Net income -21.27M -33.29M -40.44M -19.34M -2.63M
Selling general administrative 10.76M 15.17M 27.33M 20.02M 5.62M
Selling and marketing expenses 23.83M 21.72M 16.01M 10.26M 0.28M
Gross profit 10.57M 4.03M 2.00M 0.54M 9.03M
Reconciled depreciation 1.43M 1.07M 2.36M 2.21M 2.71M
Ebit -17.69M -31.36M -25.71M -19.95M -1.89M
Ebitda -16.58M -30.29M -22.62M -17.35M 0.82M
Depreciation and amortization 1.12M 1.07M 3.08M 2.60M 2.71M
Operating income -17.98M -31.33M -25.71M -19.95M -1.89M
Other operating expenses 43.16M 44.42M 30.17M 21.47M 12.54M
Interest expense 3.09M 0.82M 0.39M 0.01M 0.00M
Tax provision 0.63M 0.92M 0.36M -0.23M 0.74M
Interest income 0.27M 0.52M 0.72M 0.40M 0.00M
Net interest income -3.61M -0.50M 0.33M 0.39M 0.00M
Income tax expense 0.49M 0.92M 0.36M -0.23M 0.74M
Total revenue 25.18M 13.09M 4.47M 1.52M 10.39M
Total operating expenses 37.80M 35.36M 27.70M 20.49M 11.19M
Cost of revenue 14.61M 9.06M 2.47M 0.98M 1.35M
Total other income expense net -2.81M -1.04M -14.38M 0.39M 0.27M
Net income from continuing ops -27.18M -33.29M -40.44M -19.34M -2.63M
Net income applicable to common shares - - -40.44M -19.34M -2.63M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 45.90M 48.80M 22.07M 44.41M 32.53M
Intangible assets 14.51M 16.86M 11.78M 26.85M 27.27M
Other current assets 0.00M 3.51M - 3.51M 0.91M
Total liab 46.95M 26.49M 16.65M 3.38M 2.25M
Total stockholder equity -1.05M 11.79M 5.43M 41.03M 30.28M
Deferred long term liab - - - 9.53M 8.43M
Other current liab 7.18M 6.25M 1.06M 0.11M 0.75M
Common stock 15.90M 11.78M 3.89M 3.24M 1.76M
Capital stock 19.91M 15.01M 3.89M 3.24M 1.76M
Retained earnings -172.95M -233.53M -146.64M -106.59M -88.25M
Other liab - - 0.47M - -
Other assets - -10.52M - 9.53M 8.43M
Cash 5.61M 13.95M 2.82M 12.12M 2.94M
Total current liabilities 26.05M 10.77M 10.64M 3.38M 2.25M
Current deferred revenue - 0.00M - - -
Net debt 15.45M 6.46M 3.28M -11.96M -2.91M
Short term debt 0.35M 0.38M 0.09M 0.16M 0.03M
Short long term debt total 21.06M 20.41M 6.10M 0.16M 0.03M
Other stockholder equity 197.67M 233.54M 148.17M 144.39M 116.76M
Property plant equipment - - 0.20M 0.30M 0.03M
Total current assets 30.29M 31.26M 10.09M 17.26M 5.23M
Net tangible assets - - -6.36M 23.71M 11.44M
Short term investments - -3.01M - - -
Net receivables 20.16M 10.60M 5.38M 1.77M 0.66M
Long term debt 26.17M 19.84M 6.01M - -
Inventory 4.52M 3.20M 1.46M 1.64M 1.38M
Accounts payable 18.51M 4.05M 9.49M 3.11M 1.47M
Accumulated other comprehensive income -6.23M -6.63M - - -
Common stock total equity - - - - 1.76M
Non currrent assets other 0.00M -3.64M - 26.85M -
Non current assets total 15.60M 17.54M 11.98M 27.16M 27.30M
Capital lease obligations 0.20M 0.41M 0.09M 0.16M 0.03M
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments -2.15M -2.43M -1.70M -2.05M -0.02M
Change to liabilities - - 6.03M 1.64M -2.08M
Total cashflows from investing activities -1.89M -2.43M -1.70M -2.05M -0.02M
Net borrowings 0.00M 24.00M 8.10M -0.08M -0.05M
Total cash from financing activities 4.21M 49.66M 7.71M 27.58M -0.05M
Change to operating activities - - 0.95M -0.52M 0.15M
Net income -21.27M -33.29M -40.44M -19.34M -2.63M
Change in cash -5.33M 10.55M -9.30M 9.18M -1.20M
Begin period cash flow 10.94M 3.40M 12.12M 2.94M 4.14M
End period cash flow 5.61M 13.95M 2.82M 12.12M 2.94M
Total cash from operating activities -7.01M -37.13M -18.25M -16.74M -1.40M
Issuance of capital stock 0.12M 26.82M 0.09M 27.70M 0.01M
Depreciation 1.12M 1.07M 2.36M 2.21M 2.71M
Other cashflows from investing activities - -2.19M 0.20M 0.01M 0.00M
Change to inventory -1.92M -1.16M 0.18M -0.26M -0.43M
Change to account receivables -0.89M -5.64M -2.45M -2.88M -0.26M
Sale purchase of stock - 0.00M -0.08M - -
Other cashflows from financing activities -0.17M -1.16M 7.70M -0.12M -0.05M
Change to netincome - - 15.13M 2.40M 1.15M
Capital expenditures 0.03M 2.95M 1.90M 2.06M 0.02M
Change in working capital 12.58M -7.02M 4.71M -2.01M -2.62M
Stock based compensation 0.86M 0.88M 0.74M 0.99M 0.77M
Other non cash items 0.57M 1.25M 14.38M -0.35M -0.27M
Free cash flow -7.03M -40.07M -20.14M -18.80M -1.42M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Stock Name
Change
(GBX)
Price
(GBX)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
STX
Shield Therapeutics plc		 -0.17
3.09%		 5.33 - 65.36 2.24 76.33 3.34 -1.49
HLN
Haleon PLC		 -4.20
1.10%		 376.00 20.24 18.94 2.95 2.02 3.68 14.19
HIK
Hikma Pharmaceuticals PLC		 4.00
0.24%		 1704.00 9.73 9.03 0.85 1.45 1.53 6.07
HCM
HUTCHMED China Ltd		 -2.00
0.95%		 208.00 5.38 19.30 3.37 2.02 2.25 2.40
AGY
Allergy Therapeutics		 -
-%		 4.25 - 106.38 11.72 159.47 12.12 -4.15

Profile*

Shield Therapeutics plc

Shield Therapeutics plc, a commercial stage specialty pharmaceutical company, focuses on development and commercialization of clinical-stage pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was incorporated in 2008 and is based in Gateshead, the United Kingdom.

Northern Design Centre, Gateshead, United Kingdom, NE8 3DF

44 1915 118 500

https://www.shieldtherapeutics.com

63

Name Title Year Born
Mr. Gregory P. Madison CEO & Exec. Director 1968
Dr. Christian Schweiger M.D., Ph.D. Co-Founder & Non Exec. Director 1967
Mr. Hans-Peter Rudolf Chief Financial Officer NA
Ms. Lucy Huntington-Bailey Gen. Counsel & Company Sec. NA
Ms. Suzanne Wood Group HR Director NA
Ms. Carol Akinola Head of Pharmacovigilance & Medical Information NA
Dr. José A. Menoyo M.D. Chief Medical Officer NA
Mr. Anders Lundstrom CEO & Executive Director 1962
Dr. Christian Schweiger M.D., Ph.D. Co-Founder & Non Executive Director 1966
Mr. Santosh Shanbhag Chief Financial Officer 1978

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

DAR
GBX 8.30
+23.42%
VTY
GBX 276.20
+8.23%
GTCO
GBX 0.09
+6.98%
GLV
GBX 2.34
+6.36%
BUR
GBX 249.20
+5.95%
TMI
GBX 0.72
-6.49%
HSBA
GBX 1291.40
-5.42%
RKT
GBX 5218.00
-4.85%
TGA
GBX 643.00
-4.03%
RKH
GBX 61.70
-3.89%

Equity Sectors*

  • Basic Materials

    -1.70%

  • Communication Services

    +0.33%

  • Consumer Cyclical

    +0.45%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.25%

  • Financial Services

    +0.49%

  • Healthcare

    +0.20%

  • Industrials

    +0.74%

  • Real Estate

    +1.71%

  • Technology

    -2.81%

  • Utilities

    +0.28%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Cookies on this website

We use some essential cookies to make this site work. We also set analytics and marketing cookies, described below, to understand how you use the site and to measure our advertising. For more detailed information, see our Cookie Policy, Privacy Policy and Terms and Conditions.

Essential cookies

These cookies are necessary for core functionality, such as security, your shopping cart, remembering your cookie choice, and your progress through a report or free-trial request you started. They always need to be on.

Analytics cookies

We use analytics cookies to understand how visitors use the site — the pages visited, time spent, and where visitors came from.

Marketing cookies

These help us measure how effective our advertising is, such as recording actions you take after clicking one of our ads. If you don't enable this, you may still see our ads, but they won't be measured this way.

Support

Hi! How can we help you today?

Loading…